MedTrace Logo

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

NCT01733004 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2016-08-04

No results posted yet for this study

Summary

This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.

Conditions

Interventions

DRUG

MM-141

Sponsors & Collaborators

  • Merrimack Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chrystal Louis, MD, MPH · Merrimack Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-01-31

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01733004 on ClinicalTrials.gov